Welcome to the Thombs Research Team Website!

Dr. Brett Thombs is a Professor in the Faculty of Medicine at McGill University, a Senior Investigator at the Lady Davis Institute for Medical Research at the Jewish General Hospital, Chair of the Canadian Task Force on Preventive Health Care and Director of the Scleroderma Patient-centered Intervention Network (SPIN) and Director of the DEPRESsion Screening Data (DEPRESSD) Project.

Members of the Thombs Research Team work in three projects or areas: (1) SPIN, (2) the DEPRESSD Project, and (3) meta research and policy, which includes the Canadian Task Force on Preventive Health Care (CTFPHC), the development of an extension of the CONsolidated Standards of Reporting Trials (CONSORT) statement for trials conducted in cohorts and other routinely collected data, and other meta-research projects.

Each project group includes research coordinators, research assistants, postdoctoral fellows, graduate and undergraduate students who collaboratively work on various aspects of the projects. Check out the individual project sections to learn more about each project team and our current team members.

Latest News...


Dr. Thombs in the news – COVID-19 and Mental Health in Quebec and Canada | 2020/07/06

The Task Force, led by Dr. Thombs, published a new guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesopageal reflus disease without alarm symptoms. The Task Force develops and disseminates guidance for prevention in Canadian primary care. This new guideline reports that evidence does not support screening and that resources would be used more wisely for other services with evidence of benefit for patients. Link to guideline:


SPIN-CHAT Trial Funding from the Canadian Institutes of Health Research | 2020/07/05

The SPIN COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program Trial was funded by CIHR. The trial tests the effects of a muti-faceted video-conference-based group mental health intervention on anxiety and other mental health symptoms. The trial was launched with funds from the McGill Interdisciplinary Initiative in Infection and Immunity Emergency COVID-19 Research Fund and generous contributions fromScleroderma Canada, made possible by an educational grant for patient support programming from Boehringer Ingelheim; the Scleroderma Society of Ontario; Scleroderma Manitoba; Scleroderma Atlantic; Scleroderma Australia; Scleroderma New South Wales; Scleroderma Victoria; Scleroderma Queensland; Scleroderma SASK; Scleroderma Association of BC; and Sclérodermie Québec. Results for the trial will be available in July. Link to trial protocol:

Screen Shot 2020-06-19 at 10.24.50

Dr. Thombs in the news – COVID-19 and Mental Health in Quebec and Canada | 2020/06/19

See Dr. Thombs’ comments on a recent survey of mental health in Quebec and the rest of Canada by the Canadian Press, which appeared in the Globe and Mail (, L’actualité (, and other outlets.


The Canadian Task Force on Preventive Health Care holds its June 2020 meeting online | 2020/06/16

The Canadian Task Force on Preventive Health Care (Task Force) is holding its first ever online meeting on June 15-16, 2020. The meeting is led by Dr. Thombs (Task Force Chair) and has been organized by team members Daniela Cortinovis (Task Force Manager) and Julia Nordlund (Task Force Administrator). The Task Force typically meets in-person three times a year to discuss recommendations on screening practices, methodology for guideline development, communication activities, knowledge translation initiatives and much more! Due to COVID-19, the June 2020 meeting is being held via videoconference. More information about the Task Force guidelines and activities is available here:

Screen Shot 2020-06-09 at 1.59.31 PM.png

Congrats to Brooke Levis and the DEPRESSD team on their JAMA publication! | 2020/06/09

We are thrilled to announce that a DEPRESSD project evaluating the screening accuracy of the PHQ-2 alone and in combination with the PHQ-9 has been published in JAMA. The study, led by Brooke Levis, synthesized data from 100 studies (>44,000 participants), and found that the combination of PHQ-2 (with a cutoff of >=2) followed by the PHQ-9 (with a cutoff of >=10) had similar accuracy to PHQ-9 alone, but reduced the number of participants needing to complete the full PHQ-9 by 57%. Access the full article here:

For more news about the team, please click here ...